Key result
Elamipretide plus standard therapy is linked to LVEF recovery to ~60% in neonatal Barth syndrome.
Why the study?
Barth syndrome is a rare genetic disease with no approved curative therapies, and this report aims to further support elamipretide's role in treating infants with Barth syndrome.
Does early expanded-access elamipretide combined with standard heart failure therapy improve left ventricular ejection fraction and clinical recovery in a newborn with Barth syndrome and severe cardiomyopathy?
Case Report (n=1)
Open-label
No
Does early expanded-access elamipretide combined with standard heart failure therapy improve left ventricular ejection fraction and clinical recovery in a newborn with Barth syndrome and severe cardiomyopathy?
Early initiation of elamipretide alongside standard heart failure therapy in a critically ill newborn with Barth syndrome was well tolerated and associated with normalization of LVEF to 60%, avoiding mechanical circulatory support or heart transplantation.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in neonatal Barth cardiomyopathy; hypothesis-generating and requires prospective trials.
Background: Barth syndrome (BTHS) is a rare genetic disease, with no approved curative therapies, characterized by abnormally developed cardiolipin, resulting in mitochondrial dysfunction. Cardiomyopathy, a common clinical manifestation of BTHS, often appears in infancy. Elamipretide, an investigational drug that binds to cardiolipin on the inner mitochondrial membrane, leads to improved membrane stability, enhanced adenosine triphosphate production, and reduced reactive oxygen species. This patient case aims to further support elamipretide's role in treating BTHS infants. Case summary: with BTHS who demonstrated a moderately dilated left ventricle (LV) with an LV ejection fraction (LVEF) of 20% at birth. He was transferred to a tertiary children's hospital where he was intubated and administered medications for haemodynamic support. After several weeks, the patient was extubated and his LVEF improved, although still below normal. On day of life (DOL) 34, therapy with daily IV elamipretide (0.25 mg/kg increased to 0.5 mg/kg on DOL39) began, followed by standard-of-care oral heart failure medications. Subsequent echocardiograms demonstrated improvement of LVEF to near-normal levels. He was weaned off oxygen completely on DOL49 and discharged home on DOL61 on daily subcutaneous elamipretide 0.5 mg/kg and oral heart failure medications. His most recent echocardiogram showed improvement of LVEF to 60%. Discussion: Our case suggests that elamipretide may have contributed to the improvement of LV function in this BTHS infant, supporting elamipretide's early use in BTHS. Our findings align with the previous studies in which elamipretide treatment demonstrated normalization of mitochondrial function and improvement in LV function.
No takes yet. Share an insight, caveat, or question.
Ortmann et al. (2025) conducted a case report in Barth syndrome with cardiomyopathy (n=1). Elamipretide was evaluated on Left ventricular ejection fraction (LVEF) on echocardiogram at day of life 88. Elamipretide combined with standard heart failure therapy was associated with LVEF improvement from 20% at birth to 49% at discharge (DOL 61) and 60% at DOL 88 in a newborn with Barth syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: